US patent infringement investigation targets German drug price control measures
If investigators uncover violations, this could enable the USTR to pursue unilateral action against Germany.
Pricing and Market Access
CDA data reveals trends on drug approvals and reimbursements in Canada
Healthcare cost inflation is back in the headlines
Japan’s FY26 price revision expands G1 repricing and drives price reduction
MFN changing the rules of the game for the Nordic countries
The Most Favored Nation Policy: early insights into Europe’s response
GlobalData’s key thoughts from World EPA Congress 2026
Market instability expected from South Korea’s new pricing reform in 2026-2028
